Modified-blind, randomized, multicenter, single dose, two-way crossover study of arformoterol tartrate [arformoterol] inhalation solution 15microg BID vs. 30microg QD in subjects with (COPD) [chronic obstructive pulmonary disease].

Trial Profile

Modified-blind, randomized, multicenter, single dose, two-way crossover study of arformoterol tartrate [arformoterol] inhalation solution 15microg BID vs. 30microg QD in subjects with (COPD) [chronic obstructive pulmonary disease].

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Feb 2012

At a glance

  • Drugs Arformoterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 01 Aug 2009 Results reported in Clinical Therapeutics.
    • 03 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 20 May 2009 Results were reported at the 105th International Conference of the American Thoracic Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top